PACIFIC EDGE LIMITED — Capital/Financing Update 2017

Mar 21, 2017

21 March 2017 Company Announcement

==> picture [225 x 57] intentionally omitted <==

CALLAGHAN INNOVATION GROWTH GRANT FOR PACIFIC EDGE

Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) is pleased to advise that it has received an additional grant of up to $3 million to its existing Growth Grant from Callaghan Innovation to enable further research and development of its leading edge cancer diagnostics technology.

Pacific Edge received an initial grant of $4.5 million in February 2014, with funding spread over three years. The grant has been successfully utilised by Pacific Edge to underwrite the development of its suite of Cxbladder products. During the term of the grant Pacific Edge completed and commercialised three products, Cxbladder Triage, Cxbladder Monitor and Cxbladder Resolve. Review by Callaghan Innovation has resulted in the allocation of up to a further $3 million to be spread over two years.

Pacific Edge’s non-invasive, cost effective and easy-to-use, urine-based cancer detection and management tests provide clinicians with accurate data and enhance early detection and timely management of patients.

Since the initial grant was awarded, Pacific Edge has developed and launched three new products in its suite of Cxbladder bladder cancer diagnostics tests, in addition to its original test. All of the four tests address different clinical needs throughout the bladder cancer detection and management pathways - from investigation of haematuria (blood in the urine) through to the management of patients who have the disease and are being regularly monitored in the clinic for recurrence of urothelial cancer.

CEO of Pacific Edge, David Darling, said: “Investment into research and development is a major focus for Pacific Edge and we are continually looking at how we can provide better and more targeted diagnostic tools for clinicians and their patients. The Growth Grant supplements Pacific Edge’s own investment into R&D and will enable us to bring new innovations through into new products and product improvements, for the benefit of both clinicians and patients alike.”

ENDS

For more information contact:

David Darling Chief Executive Officer Pacific Edge Ltd P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre clinical studies.

Pacific Edge has three proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and better detection and management of urothelial cancer. Cxbladder Detect and Cxbladder Triage are available through the company’s dedicated CLIA certified laboratories for customers in New Zealand, Australia and the USA. Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated being available in the US in 2016.

21 March 2017 Company Announcement

==> picture [225 x 57] intentionally omitted <==

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients’ urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the company’s CLIA certified laboratories. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient’s urine, with patient specific clinical factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires lifelong surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com

Cxbladder Resolve is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient’s urine, with patient characteristics for the identification of patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.